SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response

As the SARS-CoV-2 pandemic continues to rage worldwide, the emergence of numerous variants of concern (VOC) represents a challenge for the vaccinal protective efficacy and the reliability of commercially available high-throughput immunoassays. Our study demonstrates the administration of two doses o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mileto, D., Fenizia, C., Cutrera, M., Gagliardi, G., Gigantiello, A., De Silvestri, A., Rizzo, A., Mancon, A., Bianchi, M., De Poli, F., Cuomo, M., Burgo, I., Longo, M., Rimoldi, S. G., Pagani, C., Grosso, S., Micheli, V., Rizzardini, G., Grande, R., Biasin, M., Gismondo, M. R., Lombardi, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Emerging and Re-Emerging Coronaviruses
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648019/
https://www.ncbi.nlm.nih.gov/pubmed/34749573
http://dx.doi.org/10.1080/22221751.2021.2004866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648019/
https://www.ncbi.nlm.nih.gov/pubmed/34749573
http://dx.doi.org/10.1080/22221751.2021.2004866

Ejemplares similares